<!DOCTYPE html>
<html lang="en">
  <head>
    <meta charset="UTF-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=edge" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <link rel="stylesheet" href="style.css" />
    <link rel="preconnect" href="https://fonts.googleapis.com" />
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin />
    <link
      href="https://fonts.googleapis.com/css2?family=Noto+Sans+SC:wght@400;700&display=block"
      rel="stylesheet"
    />
    <title>Wenlong Li</title>
  </head>

  <body>
    <span class="lang-select">[ <a href="./">en</a> | æ±‰è¯­ ]</span>
    <div class="grid">
      <div class="headshot"></div>
      <div class="bio">
        <img src="headshot.jpg" class="headshot" />

        <h1>ğŸ‘‹ ä½ å¥½ï¼æˆ‘æ˜¯ææ–‡é¾™ã€‚</h1>

        <h2>
          ğŸ”¬ ç°åœ¨äº
          <a href="https://www.cruk.cam.ac.uk/"
            >Cancer Research UK Cambridge Institute, University of Cambridge</a
          >åšåšå£«åç ”ç©¶ã€‚
        </h2>

        <p>
          ğŸ‘¨â€ğŸ”¬ As a dedicated and experienced researcher, I work in academia to
          discover new treatments for seemingly incurable diseases. I previously
          investigated the pharmacology of drugs, and have now changed field to
          focus on understanding the molecular mechanisms that drive
          pathological states.
        </p>

        <p>
          âš•ï¸ My current research is within the
          <a href="https://www.cruk.cam.ac.uk/research-groups/biffi-group"
            >Biffi Group</a
          >, working to help identify treatments for
          <a
            href="https://www.pancreaticcancer.org.uk/information/just-diagnosed-with-pancreatic-cancer/pancreatic-ductal-adenocarcinoma-and-other-exocrine-tumours/"
            >pancreatic ductal adenocarcinoma (PDAC)</a
          >. I am especially focussed on
          <a href="https://en.wikipedia.org/wiki/Chronic_pancreatitis"
            >chronic pancreatitis</a
          >, which is a debilitating condition and a major risk factor for PDA.
        </p>

        <p>My particular areas of expertise include ğŸ mouse models, etc...</p>
      </div>

      <div class="contact">
        <h2>Find Me</h2>
        <ul>
          <li>
            <b>LinkedIn:</b>
            <a href="https://www.linkedin.com/in/wenlong-li-89087515b/"
              >Wenlong Li</a
            >
          </li>
          <li>
            <b>ORCID:</b>
            <a href="https://orcid.org/0000-0002-5507-3042"
              >0000-0002-5507-3042</a
            >
          </li>
          <li>
            <b>Email:</b>
            <a href="mailto:wenlong.li@cruk.cam.ac.uk"
              >wenlong.li@cruk.cam.ac.uk</a
            >
          </li>
        </ul>
      </div>

      <div class="pubs">
        <h2>Publications</h2>
        <ul>
          <li>
            <p>
              <a href="https://doi.org/10.1016/j.ejpb.2022.06.008">
                Li W, LehutovÃ¡ D, Sparidans RW, Heydari P, Wang J, Lebre MC,
                Beijnen JH, Schinkel AH.<br />
                ABCB1 restricts brain accumulation of the novel RORÎ³ agonist
                cintirorgon, while OATP1A/1B and CYP3A limit its oral
                availability.<br />
                Eur J Pharm Biopharm. 2022 Aug;177:135-146.
              </a>
            </p>
          </li>
          <li>
            <p>
              <a href="https://doi.org/10.1002/ijc.32568">
                Li W, Tibben M, Wang Y, Lebre MC, Rosing H, Beijnen JH, Schinkel
                AH.<br />
                P-glycoprotein (MDR1/ABCB1) controls brain accumulation and
                intestinal disposition of the novel TGF-Î² signaling pathway
                inhibitor galunisertib.<br />
                Int J Cancer. 2020 Mar 15;146(6):1631-1642.
              </a>
            </p>
          </li>
          <li>
            <p>
              <a href="https://doi.org/10.1016/j.phrs.2018.09.020">
                Li W, Sparidans RW, Wang Y, Lebre MC, Beijnen JH, Schinkel
                AH.<br />
                P-glycoprotein and breast cancer resistance protein restrict
                brigatinib brain accumulation and toxicity, and, alongside
                CYP3A, limit its oral availability.<br />
                Pharmacol Res. 2018 Nov;137:47-55.
              </a>
            </p>
          </li>
        </ul>
      </div>
    </div>
  </body>
</html>
